Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A2 | O00482 | 1/20 | 0.36 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | F2R | P25116 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28180252 | 0.95 | NR5A2 (0.35) | NR5A2NR5A1GAAHTTALDH1A1 | |
| SCHEMBL31364 | 0.88 | GAA (0.36) | GAAHTTALDH1A1MAPK1NPSR1 | |
| SCHEMBL9715394 | 0.85 | GAA (0.38) | GAAXBP1NPSR1F2R | |
| SCHEMBL10789383 | 0.84 | SGPL1 (0.31) | — | |
| SCHEMBL38993 | 0.84 | ALDH1A1 (0.35) | NR5A2NR5A1GAAHTTALDH1A1 | |
| SCHEMBL29487596 | 0.84 | ALDH1A1 (0.35) | NR5A2NR5A1GAAHTTALDH1A1 | |
| SCHEMBL11213179 | 0.84 | GAA (0.35) | GAAHTTALDH1A1MAPK1NPSR1 | |
| SCHEMBL13599592 | 0.83 | GAA (0.36) | GAAHTTALDH1A1MAPK1NPSR1 | |
| SCHEMBL11487382 | 0.83 | GAA (0.35) | GAAHTTALDH1A1MAPK1NPSR1 | |
| SCHEMBL1768974 | 0.83 | GAA (0.35) | GAAHTTALDH1A1MAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731727-A1 | HALF-WAVE PLATE | Merck Patent GmbH (DE) | 2026-04-29 | — | — | EP | disclosed |
| EP-4713414-A1 | OPTICAL ELEMENT COMPRISING A CHIRAL LC POLYMER FILM | Merck Patent GmbH (DE) | 2026-03-25 | — | — | EP | disclosed |
| EP-4713413-A1 | CHIRAL REACTIVE MESOGEN MIXTURE | Merck Patent GmbH (DE) | 2026-03-25 | — | — | EP | disclosed |
| US-20260071126-A1 | Polymerizable Liquid Crystal Material and Polymerized Liquid Crystal Film | MERCK PATENT GMBH (DE) | 2026-03-12 | — | — | US | disclosed |
| US-12570900-B2 | Polymerisable compound, polymerisable LC material and polymer film | MERCK PATENT GMBH (DE) | 2026-03-10 | — | — | US | disclosed |
| US-12565617-B2 | Polymerisable oligomeric liquid crystal, polymerisable medium and polymerised liquid crystal film | MERCK PATENT GMBH (DE) | 2026-03-03 | — | — | US | disclosed |
| EP-4689004-A1 | CHIRAL REACTIVE MESOGEN MIXTURE | Merck Patent GmbH (DE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4689002-A1 | REACTIVE MESOGENS WITH HIGH BIREFRINGENCE | Merck Patent GmbH (DE) | 2026-02-11 | — | — | EP | disclosed |
| US-20250361445-A1 | POLYMERISABLE LIQUID CRYSTAL MEDIUM AND POLYMERISED LIQUID CRYSTAL FILM | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | US | disclosed |
| EP-4590786-A1 | POLYMERISABLE LIQUID CRYSTAL MEDIUM AND POLYMERISED LIQUID CRYSTAL FILM | Merck Patent GmbH (DE) | 2025-07-30 | — | — | EP | disclosed |
| US-20030083406-A1 | 4-Formyl amino-n-methylpiperidine derivatives, the use thereof as stabilisers and organic material stabilised therewith | BASF AKTIENGESELLSCHAFT (DE) | 2003-05-01 | — | — | US | disclosed |
| US-20030060544-A1 | Stabilizer composition | BASF AKTIENGESELLSCHAFT (DE) | 2003-03-27 | — | — | US | disclosed |
| EP-0309401-B2 | Stabilization of coatings with N-hydroxy hindered amines | CIBA SC HOLDING AG (CH) | 2002-06-05 | — | — | EP | disclosed |
| WO-2002042368-A2 | METHOD FOR STABILIZING POLYOLEFINS | BASF AKTIENGESELLSCHAFT (DE) | 2002-05-30 | — | — | WO | disclosed |
| US-6268116-B1 | MULTILAYER; REFLECTIVE SUPPORT, PHOTOSENSITIVE LAYER | EASTMAN KODAK COMPANY | 2001-07-31 | — | — | US | disclosed |
| US-6214929-B1 | FREE RADICAL POLYMERIZATION OF AN ETHYLENICALLY UNSATURATED MONOMER | BASF AKTIENGESELLSCAFT (DE) | 2001-04-10 | — | — | US | disclosed |
| EP-0942037-A1 | Polymer dispersions or solutions containing stabilisers and polymer preparations obtainable therefrom | BASF AKTIENGESELLSCHAFT (DE) | 1999-09-15 | — | — | EP | disclosed |
| EP-0309401-B1 | Stabilization of coatings with N-hydroxy hindered amines | CIBA GEIGY AG (CH) | 1994-10-26 | — | — | EP | disclosed |
| US-5006577-A | Durable, weatherproof | CIBA-GEIGY CORPORATION (US) | 1991-04-09 | — | — | US | disclosed |
| EP-0309401-A1 | Stabilization of coatings with N-hydroxy hindered amines | CIBA-GEIGY AG (CH) | 1989-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083406-A1 | 4-Formyl amino-n-methylpiperidine derivatives, the use thereof as stabilisers and organic material stabilised therewith | PNMT, INMT, AZI2 | NR5A2 3075/4885NR5A1 3194/4885GAA 3877/4885 |
| US-12570900-B2 | Polymerisable compound, polymerisable LC material and polymer film | L3MBTL3, L3MBTL1, L3MBTL4 | NR5A2 3781/4885NR5A1 3603/4885GAA 4865/4885 |
| US-20260071126-A1 | Polymerizable Liquid Crystal Material and Polymerized Liquid Crystal Film | MLX, SCO2, VCL | NR5A2 2084/4885NR5A1 765/4885GAA 4847/4885 |
| US-12565617-B2 | Polymerisable oligomeric liquid crystal, polymerisable medium and polymerised liquid crystal film | NOD1, OSTC, MLX | NR5A2 392/4885NR5A1 70/4885GAA 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.